These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphoma. Frankel AE; Zuckero SL; Mankin AA; Grable M; Mitchell K; Lee YJ; Neville DM; Woo JH Curr Drug Targets; 2009 Feb; 10(2):104-9. PubMed ID: 19199905 [TBL] [Abstract][Full Text] [Related]
3. Immunotoxins show rapid entry of diphtheria toxin but not ricin via the T3 antigen. Youle RJ; Uckun FM; Vallera DA; Colombatti M J Immunol; 1986 Jan; 136(1):93-8. PubMed ID: 3079613 [TBL] [Abstract][Full Text] [Related]
4. Preclinical studies in rats and squirrel monkeys for safety evaluation of the bivalent anti-human T cell immunotoxin, A-dmDT390-bisFv(UCHT1). Woo JH; Bour SH; Dang T; Lee YJ; Park SK; Andreas E; Kang SH; Liu JS; Neville DM; Frankel AE Cancer Immunol Immunother; 2008 Aug; 57(8):1225-39. PubMed ID: 18256829 [TBL] [Abstract][Full Text] [Related]
5. Effect of pre-existing anti-diphtheria toxin antibodies on T cell depletion levels following diphtheria toxin-based recombinant anti-monkey CD3 immunotoxin treatment. Matar AJ; Pathiraja V; Wang Z; Duran-Struuck R; Gusha A; Crepeau R; Tasaki M; Sachs DH; Huang CA Transpl Immunol; 2012 Aug; 27(1):52-4. PubMed ID: 22676970 [TBL] [Abstract][Full Text] [Related]
6. GMP production and characterization of the bivalent anti-human T cell immunotoxin, A-dmDT390-bisFv(UCHT1) for phase I/II clinical trials. Woo JH; Liu JS; Kang SH; Singh R; Park SK; Su Y; Ortiz J; Neville DM; Willingham MC; Frankel AE Protein Expr Purif; 2008 Mar; 58(1):1-11. PubMed ID: 18160309 [TBL] [Abstract][Full Text] [Related]
7. Improved binding of a bivalent single-chain immunotoxin results in increased efficacy for in vivo T-cell depletion. Thompson J; Stavrou S; Weetall M; Hexham JM; Digan ME; Wang Z; Woo JH; Yu Y; Mathias A; Liu YY; Ma S; Gordienko I; Lake P; Neville DM Protein Eng; 2001 Dec; 14(12):1035-41. PubMed ID: 11809934 [TBL] [Abstract][Full Text] [Related]
8. Improvement of a recombinant anti-monkey anti-CD3 diphtheria toxin based immunotoxin by yeast display affinity maturation of the scFv. Wang Z; Kim GB; Woo JH; Liu YY; Mathias A; Stavrou S; Neville DM Bioconjug Chem; 2007; 18(3):947-55. PubMed ID: 17352456 [TBL] [Abstract][Full Text] [Related]
9. Genetic construction and characterization of an anti-monkey CD3 single-chain immunotoxin with a truncated diphtheria toxin. Ma S; Hu H; Thompson J; Stavrou S; Scharff J; Neville DM Bioconjug Chem; 1997; 8(5):695-701. PubMed ID: 9327133 [TBL] [Abstract][Full Text] [Related]
10. An anti-CD3 single-chain immunotoxin with a truncated diphtheria toxin avoids inhibition by pre-existing antibodies in human blood. Thompson J; Hu H; Scharff J; Neville DM J Biol Chem; 1995 Nov; 270(47):28037-41. PubMed ID: 7499288 [TBL] [Abstract][Full Text] [Related]
11. Treatment with immunotoxin. Knechtle SJ Philos Trans R Soc Lond B Biol Sci; 2001 May; 356(1409):681-9. PubMed ID: 11375071 [TBL] [Abstract][Full Text] [Related]
12. T-cell depletion and graft survival induced by anti-human CD3 immunotoxins in human CD3epsilon transgenic mice. Weetall M; Digan ME; Hugo R; Mathew S; Hopf C; Tart-Risher N; Zhang J; Shi V; Fu F; Hammond-McKibben D; West S; Brack R; Brinkmann V; Bergman R; Neville D; Lake P Transplantation; 2002 May; 73(10):1658-66. PubMed ID: 12042656 [TBL] [Abstract][Full Text] [Related]
13. A C terminus cysteine of diphtheria toxin B chain involved in immunotoxin cell penetration and cytotoxicity. Dell'Arciprete L; Colombatti M; Rappuoli R; Tridente G J Immunol; 1988 Apr; 140(7):2466-71. PubMed ID: 2965187 [TBL] [Abstract][Full Text] [Related]
14. Antibody internalization after cell surface antigen binding is critical for immunotoxin development. Kuo SR; Alfano RW; Frankel AE; Liu JS Bioconjug Chem; 2009 Oct; 20(10):1975-82. PubMed ID: 19785403 [TBL] [Abstract][Full Text] [Related]
15. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma. Vallera DA; Todhunter DA; Kuroki DW; Shu Y; Sicheneder A; Chen H Clin Cancer Res; 2005 May; 11(10):3879-88. PubMed ID: 15897589 [TBL] [Abstract][Full Text] [Related]
16. In vivo administration of anti-CD3 monoclonal antibodies or immunotoxins in murine recipients of allogeneic T cell-depleted marrow for the promotion of engraftment. Blazar BR; Hirsch R; Gress RE; Carroll SF; Vallera DA J Immunol; 1991 Sep; 147(5):1492-503. PubMed ID: 1831826 [TBL] [Abstract][Full Text] [Related]
17. Expression of an anti-CD3 single-chain immunotoxin with a truncated diphtheria toxin in a mutant CHO cell line. Liu YY; Gordienko I; Mathias A; Ma S; Thompson J; Woo JH; Neville DM Protein Expr Purif; 2000 Jul; 19(2):304-11. PubMed ID: 10873546 [TBL] [Abstract][Full Text] [Related]
18. The effect of anti-CD3-immunotoxin on T lymphocyte function in vitro. Meng G; Jiang Y; Hubbard W; Thomas JM Transpl Immunol; 1998 Mar; 6(1):53-9. PubMed ID: 9640629 [TBL] [Abstract][Full Text] [Related]
19. A fold-back single-chain diabody format enhances the bioactivity of an anti-monkey CD3 recombinant diphtheria toxin-based immunotoxin. Kim GB; Wang Z; Liu YY; Stavrou S; Mathias A; Goodwin KJ; Thomas JM; Neville DM Protein Eng Des Sel; 2007 Sep; 20(9):425-32. PubMed ID: 17693455 [TBL] [Abstract][Full Text] [Related]
20. Molecular modification of a recombinant, bivalent anti-human CD3 immunotoxin (Bic3) results in reduced in vivo toxicity in mice. Vallera DA; Todhunter D; Kuroki DW; Shu Y; Sicheneder A; Panoskaltsis-Mortari A; Vallera VD; Chen H Leuk Res; 2005 Mar; 29(3):331-41. PubMed ID: 15661270 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]